** Shares of drugmaker Ardelyx ARDX.O up 4.4% at $5.41 premarket
** ARDX says Chinese health regulator approved its drug, tenapanor, which helps control phosphate levels in dialysis patients with chronic kidney disease who don't respond well to other treatments
** Approval triggers a $5 million payment to ARDX from its Chinese partner, Shanghai Fosun Pharma 600196.SS
** ARDX is eligible for up to $100 million in further milestones and royalties from Fosun Pharma on net sales
** Fosun Pharma will market tenapanor in China, Hong Kong and Macau under the brand name Wan Ti Le
** The drug was approved by U.S. FDA in 2023 under the brand name Xphozah
** ARDX fell 16.2% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。